Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine

Overview

Journal Curr Epidemiol Rep

Specialty Public Health

Date 2022 Sep 12

PMID 36090700

Authors

Rayjean J Hung

Elham Khodayari Moez

Shana J Kim

Sanjeev Budhathoki

Jennifer D Brooks

Affiliations

Soon will be listed here.

Abstract

Purpose Of The Review: The goal of this review is to highlight emerging biomarker research by the key phases of the cancer continuum and outline the methodological considerations for biomarker application.

Recent Findings: While biomarkers have an established role in targeted therapy and to some extent, disease monitoring, their role in early detection and survivorship remains to be elucidated. With the advent of omics technology, the discovery of biomarkers has been accelerated exponentially, therefore careful consideration to ensure an unbiased study design and robust validity is crucial.

Summary: The rigor of biomarker research holds the key to the success of precision health care. The potential clinical utility and the feasibility of implementation should be central to future biomarker research study design.

Citing Articles

Research Trends and Development Dynamics of qPCR-based Biomarkers: A Comprehensive Bibliometric Analysis.

Liu L, Mu B, Zhou Y, Wu Q, Li B, Wang D Mol Biotechnol. 2025; .

PMID: 39843617 DOI: 10.1007/s12033-024-01356-7.

Development of a monoclonal antibody to ITPRIPL1 for immunohistochemical diagnosis of non-small cell lung cancers: accuracy and correlation with CD8 T cell infiltration.

Deng S, Shi J, Sun Y, Quan Y, Shen Z, Wang Y Front Cell Dev Biol. 2024; 11:1297211.

PMID: 38188019 PMC: 10770237. DOI: 10.3389/fcell.2023.1297211.

Clinical Network Systems Biology: Traversing the Cancer Multiverse.

Mambetsariev I, Fricke J, Gruber S, Tan T, Babikian R, Kim P J Clin Med. 2023; 12(13).

PMID: 37445570 PMC: 10342467. DOI: 10.3390/jcm12134535.

References

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen S, Ekman D . Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014; 9(4):e95192. PMC: 3995906. DOI: 10.1371/journal.pone.0095192. View

Mertins P, Mani D, Ruggles K, Gillette M, Clauser K, Wang P . Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016; 534(7605):55-62. PMC: 5102256. DOI: 10.1038/nature18003. View

Winkler E, Knoppers B . Ethical challenges of precision cancer medicine. Semin Cancer Biol. 2020; 84:263-270. DOI: 10.1016/j.semcancer.2020.09.009. View

Corcoran R, Chabner B . Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med. 2018; 379(18):1754-1765. DOI: 10.1056/NEJMra1706174. View

Turnbull C, Scott R, Thomas E, Jones L, Murugaesu N, Pretty F . The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018; 361:k1687. DOI: 10.1136/bmj.k1687. View

Chu J, Sun N, Hu W, Chen X, Yi N, Shen Y . The Application of Bayesian Methods in Cancer Prognosis and Prediction. Cancer Genomics Proteomics. 2021; 19(1):1-11. PMC: 8717957. DOI: 10.21873/cgp.20298. View

Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

Bojesen S, Timpson N, Relton C, Davey Smith G, Nordestgaard B . (cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality. Thorax. 2017; 72(7):646-653. PMC: 5520281. DOI: 10.1136/thoraxjnl-2016-208789. View

10.

Kwon Y, Jo H, Bae S, Seo Y, Song P, Song M . Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. Front Med (Lausanne). 2021; 8:747333. PMC: 8492935. DOI: 10.3389/fmed.2021.747333. View

11.

Chatterjee N, Shi J, Garcia-Closas M . Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016; 17(7):392-406. PMC: 6021129. DOI: 10.1038/nrg.2016.27. View

12.

Wang L, Li J, Xiong X, Hao T, Zhang C, Gao Z . Volatile organic compounds as a potential screening tool for neoplasm of the digestive system: a meta-analysis. Sci Rep. 2021; 11(1):23716. PMC: 8660806. DOI: 10.1038/s41598-021-02906-8. View

13.

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View

14.

Dagnino S, Bodinier B, Guida F, Smith-Byrne K, Petrovic D, Whitaker M . Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer. Cancer Res. 2021; 81(13):3738-3748. PMC: 7611235. DOI: 10.1158/0008-5472.CAN-20-3454. View

15.

Tammemagi M, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J . USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2021; 23(1):138-148. PMC: 8716337. DOI: 10.1016/S1470-2045(21)00590-8. View

16.

Prince C, Hammerton G, Taylor A, Anderson E, Timpson N, Davey Smith G . Investigating the impact of cigarette smoking behaviours on DNA methylation patterns in adolescence. Hum Mol Genet. 2018; 28(1):155-165. PMC: 6298233. DOI: 10.1093/hmg/ddy316. View

17.

Leung E, Han K, Zou J, Zhao Z, Zheng Y, Wang T . HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA. Clin Cancer Res. 2021; 27(21):5857-5868. PMC: 9401563. DOI: 10.1158/1078-0432.CCR-19-2384. View

18.

Collins G, Reitsma J, Altman D, Moons K . Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015; 350:g7594. DOI: 10.1136/bmj.g7594. View

19.

Collins G, Dhiman P, Andaur Navarro C, Ma J, Hooft L, Reitsma J . Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence. BMJ Open. 2021; 11(7):e048008. PMC: 8273461. DOI: 10.1136/bmjopen-2020-048008. View

20.

Rittmann M, Hussung S, Braun L, Klar R, Biesel E, Fichtner-Feigl S . Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. Sci Rep. 2021; 11(1):7499. PMC: 8021576. DOI: 10.1038/s41598-021-86779-x. View